Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence

Infectious Diseases and Therapy

Volumn 5, Issue 4, 2016, Pages 491-508

  Nuño Solinís, Roberto ^a   Arratibel Ugarte, Patricia ^a   Rojo, Ander ^a   Sanchez Gonzalez, Yuri ^b  

^a UNIVERSITY OF DEUSTO   (Spain)

^b ABBVIE INC   (United States)

Author keywords

Clinical economic burden; Extrahepatic manifestations; Hepatitis C virus; Liver mortality morbidity; Sustained virologic response

Indexed keywords

ANTIVIRAL THERAPY; CAUSE OF DEATH; CHRONIC HEPATITIS C; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ERADICATION; HEALTH CARE COST; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84998772526     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-016-0134-x     Document Type: Review

References (117)

1. Shire NJ, Sherman KE. Epidemiology of hepatitis C virus: a battle on new frontiers. Gastroenterol Clin N Am. 2015;44(4):699–716 (Epub 2015/11/26. eng).
2. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view. Accessed 19 Dec 2015.
3. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016.
4. Attar BM, Van Thiel DH. Hepatitis C virus: a time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther. 2016;7(1):33–40.
5. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215–23.
6. Swan T. Overview of new treatments for hepatitis C virus: moving towards a public health agenda. http://www.who.int/selection_medicines/committees/expert/20/reviews/overview-new-treatments-HEP-C_13-Apr-15.pdf. Accessed 19 Dec 2015.
7. Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, et al. Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs? PLoS One. 2015;10(12):e0143836.
8. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9.
9. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345–60.
10. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(S5):S165–73.
11. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730–40.
12. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(11):923–30.
13. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8.e1.
14. Younossi ZM, Park H, Adeyemi A, Stepanova M, Henry L. A meta-analytic estimation of the burden of extra hepatic manifestations of hepatitis C. Gastroenterology. 2015;148(4):S503.
15. Nyberg LM, Li X, Yang SJ, Chiang K, Cheetham TC, Caparosa S, et al. The association of sustained virological response and all-cause mortality after interferon-based therapy for chronic hepatitis C (HCV) in a large U.S. community-based health care delivery system. Hepatology. 2015;62:252A.
16. Lu M, Li J, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, et al. Effect of hepatitis C antiviral therapy on all-cause mortality and development of cancer in the chronic hepatitis cohort study (CHeCS). J Hepatol. 2015;62:S618–9.
17. Jeźequel C, Bardou-Jacquet E, Desille Y, Renard I, Lainé F, Lelan C, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 years follow-up. J Hepatol. 2015;62:S589.
18. AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/sites/default/files/HCV-Guidance_October_2016_a.pdf. Accessed 1 Mar 2016.
19. Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016 (Epub 2016/01/21. Eng).
20. Kobayashi M, Hara T, Fukushima T, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained viral response reduces liver complications and total mortality among Japanese elderly with hepatitis C virus infection. Hep Intl. 2014;8(1):S179.
21. Kutala BK, Guedj J, Asselah T, Boyer N, Mouri F, Martinot-Peignoux M, et al. Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease. Antimicrob Agents Chemother. 2015;59(2):803–10.
22. Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41(6):521–31.
23. NIH. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—June 10–12, 2002. https://consensus.nih.gov/2002/2002hepatitisc2002116html.htm. Accessed 19 Dec 2015.
24. Nahon P, Bourcier V, Layese R, Petrov-Sanchez V, Guyader D, Dharancy S, et al. Benefits of HCV eradication in compensated cirrhotic patients extend beyond liver-related complications: results from the ANRS CO12 CIRVIR prospective cohort. Hepatology. 2015;62:1090A.
25. De Lisi S, Crosignani A, Roffi L, Rossi S, Boccaccio V, Zermiani P, et al. SVR is associated with no risk reduction of HCC development in patients with HCV-related cirrhosis. A prospective, up-to 23 years, cohort follow-up study. Dig Liver Dis. 2014;46:e33–4.
26. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230–6.
27. McCombs JS, Tonnu-MiHara I, Matsuda T, McGinnis J, Fox S. Can hepatitis c treatment be safely delayed? Evidence from the veterans administration healthcare system. J Hepatol. 2015;62:S191.
28. Baser O, Altinbas A, Baser E, Kariburyo MF. Economic impact and complications of treated and untreated hepatitis C virus patients in Turkey. Value Health Reg Issues. 2015;7:42–8.
29. Coldea L. The frequency and the characteristics of extrahepatic manifestations associated with chronic hepatitis C. HPB. 2015;17:96–7.
30. Yilmaz Sİ, Erol S, Özbek A, Parlak M. Distribution of viral genotypes and extrahepatic manifestations in patients with chronic hepatitis C in Eastern Turkey. Turk J Med Sci. 2015;45(1):70–5.
31. Cheng ZJ, Zhou BT, Shi XC, Zhang Y, Zhang LF, Chen LM, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J. 2014;127(7):1206–10.
32. Mazzaro C, Mauro E, Dal Maso L, Pozzato G. Prevalence of extrahepatic manifestations in infection with hepatitis C virus: study of 440 cases. Ital J Med. 2012;6(1):94.
33. Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba E. Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. Adv Med Sci. 2010;55(1):67–73.
34. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490–5 (Epub 1992/11/19. eng).
35. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–74 (Epub 2004/06/11. eng).
36. Ramos-Casals M, Robles A, Brito-Zeron P, Nardi N, Nicolas JM, Forns X, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum. 2006;36(3):189–96 (Epub 2006/09/26. eng).
37. Retamozo S, Diaz-Lagares C, Bosch X, Bove A, Brito-Zeron P, Gomez ME, et al. Life-threatening cryoglobulinemic patients with hepatitis c: clinical description and outcome of 279 patients. Medicine. 2013 (Epub 2013/08/27. Eng).
38. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696–706 (Epub 2006/11/01. eng).
39. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomark Prev. 2006;15(11):2078–85 (PMID: 17119031. Epub 2006/11/23. eng).
40. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95(9):745–52 (Epub 2004/10/09. eng).
41. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44 (Epub 2008/09/26. eng).
42. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37(6):647–52 (Epub 2013/02/07. eng).
43. Patel S, Jinjuvadia R, Patel R, Liangpunsakul S. Insulin resistance is associated with significant liver fibrosis in chronic hepatitis C patients: a systemic review and meta-analysis. J Clin Gastroenterol. 2016;50(1):80–4.
44. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6 (Epub 2007/01/16. eng).
45. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2(4):715–21 (Epub 2007/08/21. eng).
46. Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56(1):23–31 (Epub 2010/04/20. eng).
47. He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PloS one. 2013;8(11):e81305 (Epub 2013/11/23. eng).
48. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PloS one. 2012;7(2):e31527 (Epub 2012/03/01. eng).
49. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49(2):225–32 (Epub 2009/06/11. eng).
50. Younossi ZM, Henry L, Park H, Adeyemi A, Stepanova M. Depression and chronic hepatitis C (CH-C): a common and costly association. Am J Gastroenterol. 2015;110:S874–5.
51. Henry L, Whitley K, Dhakal K, Samuel L, Culler L, Bryns M, et al. A systematic review assessing the impact of chronic hepatitis C on health-related quality of life and patient-reported outcomes. Am J Gastroenterol. 2014;109:S178.
52. Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61(4):1145–53 (Epub 2014/11/29. eng).
53. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034–41 (Epub 2007/12/07. eng).
54. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739–44 (Epub 2009/01/08. eng).
55. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40(4):675–81 (Epub 2004/03/20. eng).
56. Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis c virus genotype 1 by stage of liver fibrosis in a us treatment-naive population. JAMA Intern Med. 2016;176(1):65–73.
57. Ahmed A, Gordon SC, Saab S, Younossi Z. Evaluation of the health outcomes for ledipasvir/sofosbuvir in early vs. Delayed treatment according to fibrosis stage of patients with chronic hepatitis C virus (HCV) genotype 1 infection: results from a decision-analytic markov model. Hepatology. 2014;60:1041A.
58. Buti M, Domínguez-Hernández R, Oyagüez I, Rueda M, Casado MÁ. Early versus delayed use of sofosbuvir plus peginterferon/ribavirin therapy in fibrosis patients with hepatitis C virus: a cost-effectiveness analysis. J Hepatol. 2015;62:S666.
59. Misurski DA, Johnson SJ, Samp JC, Marx SE, Juday TR, Virabhak S, et al. Reduction in annual medical costs with early treatment of HCV using abbvie 3D (ABT-450/ritonavir/ombitasvir and dasabuvir) ± ribavirin in the United States. J Hepatol. 2015;62:S642.
60. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34–59 (Epub 2014/04/10. eng).
61. Semela D, Blach S, Bihl FK, Bruggmann P, Lavanchy D, Negro F, et al. The impact of time on a scenario to minimize complications of hepatitis C infection. Hepatology. 2014;60:912A.
62. Bruggmann P, Negro F, Bihl F, Hindman S, Lavanchy D, Müllhaupt B, et al. The disease burden of chronic hepatitis C virus (HCV) infection in Switzerland. J Hepatol. 2014;60(1):S518.
63. Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, et al. Launch of a nationwide hepatitis C elimination program-Georgia, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64(28):753–7.
64. Dashdorj NJ, Genden Z, Yagaanbuyant D, Dashdorj ND. Hepatitis prevention, control, and elimination program in Mongolia: innovation in combating viral hepatitis endemic. J Viral Hepat. 2015;22:130.
65. Muir AJ, Naggie S. Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? Clin Gastroenterol Hepatol. 2015;13(12):2166–72.
66. ABC. Federal Government to spend $1 billion on groundbreaking Hepatitis C treatments. http://www.abc.net.au/news/2015-12-20/federal-government-spending-1billion-on-hepatitis-c-treatment/7043624. Accessed 19 Dec 2015.
67. IHS. French government proposes "universal" access to new HCV medicines. http://www.ihs.com/country-industry-forecasting.html?ID=10659114512. Accessed 1 Mar 2016.
68. Labarga P, Barreiro P, De Mendoza C, Soriano V. Progression to advanced liver fibrosis in HIV/HCV coinfected patients and prioritization of new hepatitis C therapies. J Hepatol. 2015;62:S651–2.
69. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36(6):1439–45 (Epub 2002/11/26. eng).
70. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42(10):2204–12 (Epub 1999/10/19. eng).
71. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46(3):420–31 (Epub 2007/01/02. eng).
72. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48(5):721–7 (Epub 2008/03/01. eng).
73. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34(1):140–7 (Epub 2001/02/24. eng).
74. Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol. 2005;11(47):7494–8 (Epub 2006/01/27. eng).
75. Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. PharmacoEconomics. 2003;21(5):341–9 (Epub 2003/03/12. eng).
76. Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussalli J, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol. 2002;36(6):812–8 (Epub 2002/06/05. eng).
77. Aghemo A, Prati GM, Rumi MG, Soffredini R, D’Ambrosio R, Orsi E, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56(5):1681–7 (Epub 2012/05/24. eng).
78. Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis. 2014;46(9):833–7 (Epub 2014/06/24. eng).
79. Kraus MR, Schafer A, Teuber G, Porst H, Sprinzl K, Wollschlager S, et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology. 2013;58(2):497–504 (Epub 2013/01/10. eng).
80. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100(3):643–51.
81. Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, et al. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. Hepato-gastroenterology. 2011;58(107–108):875–9 (Epub 2011/08/13. eng).
82. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012;56(3):549–56 (Epub 2011/10/27. eng).
83. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468–73 (Epub 2005/01/22. eng).
84. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98 (Epub 2015/08/05. eng).
85. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544–63 (Epub 2015/01/27. eng).
86. Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. J Med Econ. 2015;18(10):838–49 (Epub 2015/04/24. eng).
87. Warren E, Wright A, Jones B. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia. Value Health. 2014;17(8):792–800 (Epub 2014/12/17. eng).
88. Vellopoulou A, van Agthoven M, van der Kolk A, de Knegt RJ, Berdeaux G, Cure S, et al. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. Appl Health Econ Health Policy. 2014;12(6):647–59 (Epub 2014/08/12. eng).
89. San Miguel R, Gimeno-Ballester V, Blazquez A, Mar J. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64(8):1277–88 (Epub 2014/10/15. eng).
90. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40(6):657–75 (Epub 2014/07/30. eng).
91. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61(2):157–68 (Epub 2015/03/18. eng).
92. Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Mullhaupt B, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PloS One. 2015;10(5):e0126984 (Epub 2015/05/15. eng).
93. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2014;59(5):1692–705 (Epub 2014/04/03. eng).
94. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Dig Liver Dis. 2014;46(10):936–42 (Epub 2014/07/30. eng).
95. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407–19 (Epub 2015/03/17. eng).
96. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546–53 (Epub 2014/10/21. eng).
97. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279–90 (Epub 2012/02/22. eng).
98. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162(9):619–29 (Epub 2015/03/31. eng).
99. Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2015;22(4):376–83 (Epub 2014/09/16. eng).
100. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20(12):847–57 (Epub 2013/12/07. eng).
101. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014;60(1):37–45 (Epub 2014/03/29. eng).
102. Gimeno-Ballester V, Mar J, San Miguel R. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naive patients plus chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2015:1–10 (Epub 2015/09/04. Eng).
103. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013;13:190 (Epub 2013/04/30. eng).
104. Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy. 2013;11(1):65–78 (Epub 2013/01/29. eng).
105. Dan YY, Ferrante SA, Elbasha EH, Hsu TY. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-alpha2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore. Antivir Ther. 2015;20(2):209–16 (Epub 2014/08/12. eng).
106. Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015;22(11):882–9 (Epub 2015/04/08. eng).
107. Cure S, Guerra I, Camma C, Craxi A, Carosi G. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ. 2015;18(9):678–90 (Epub 2015/04/22. eng).
108. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17(1):77–87 (Epub 2013/09/17. eng).
109. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17(1):65–76 (Epub 2013/10/29. eng).
110. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397–406 (Epub 2015/03/17. eng).
111. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16(6):973–86 (Epub 2013/09/18. eng).
112. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 2013;11(11):1503–10 (Epub 2013/05/28. eng).
113. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850–60 (Epub 2012/03/29. eng).
114. Camma C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol. 2013;59(4):658–66 (Epub 2013/05/28. eng).
115. Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PloS One. 2014;9(3):e90295 (Epub 2014/03/08. eng).
116. Blazquez-Perez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. PharmacoEconomics. 2013;31(10):919–31 (Epub 2013/09/04. eng).
117. Athanasakis K, Ferrante SA, Kyriopoulos, II, Petrakis I, Hill M, Retsa MP, et al. Boceprevir for chronic genotype 1 hepatitis C virus in the current health care setting in Greece: a cost-effectiveness analysis. Clin Ther. 2015;37(7):1529–40 (Epub 2015/06/03. eng).